Adverse interactions between antifungal azoles and vincristine: review and analysis of cases

Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia

(2011) R. M. van Schie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction

(2011) Brad Moriyama et al.   MYCOSES

Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem - New Dilemma

(2011) Zoe Dorothea Pana et al.   PEDIATRIC BLOOD & CANCER

Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

(2010) Yanjun Li et al.   CLINICAL PHARMACOKINETICS

Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine

(2010) Sandeep Jain et al.   PEDIATRIC BLOOD & CANCER

Itraconazole for invasive fungal infection with pediatric malignancies

(2010) Ryoji Kobayashi et al.   PEDIATRICS INTERNATIONAL

Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients

(2010) Elizabeth Dodds-Ashley   PHARMACOTHERAPY

Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers

(2009) He-Ping Lei et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

(2009) Ina Scholz et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Vincristine induced neurotoxicity in cancer patients

(2009) Sunil Gomber et al.   INDIAN JOURNAL OF PEDIATRICS

Posaconazole-increased Vincristine Neurotoxicity in a Child

(2009) Céline Eiden et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Clinically relevant drug interactions of current antifungal agents

(2009) Paul O. Gubbins et al.   MYCOSES

Vincristine: Can its therapeutic index be enhanced?

(2009) Andrew Moore et al.   PEDIATRIC BLOOD & CANCER

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

(2009) Stephen Harnicar et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

(2008) Guo Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Itraconazole Oral Solution Enhanced Vincristine Neurotoxicity in Five Patients with Malignant Lymphoma

(2008) Naoto Takahashi et al.   INTERNAL MEDICINE

CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

(2008) Johanna Weiss et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X

(2008) Christopher C. Porter et al.   PEDIATRIC BLOOD & CANCER